α2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction

Yunjia Chena, Yin Penga, Pulin Chea, Mary Gannona, Yin Liua, Ling Lib, Guojun D Bu, Thomas Van Groena, Kai Jiaod, Qin Wanga

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Accumulation of amyloid β (Aβ) peptides in the brain is the key pathogenic factor driving Alzheimer's disease (AD). Endocytic sorting of amyloid precursor protein (APP) mediated by the vacuolar protein sorting (Vps10) family of receptors plays a decisive role in controlling the outcome of APP proteolytic processing and Aβ generation. Here we report for the first time to our knowledge that this process is regulated by a G protein-coupled receptor, the α2A adrenergic receptor (α2AAR). Genetic deficiency of the α2AAR significantly reduces, whereas stimulation of this receptor enhances, Aβ generation and AD-related pathology. Activation of α2AAR signaling disrupts APP interaction with a Vps10 family receptor, sort-ing- related receptor with A repeat (SorLA), in cells and in the mouse brain. As a consequence, activation of α2AAR reduces Golgi localization of APP and concurrently promotes APP distribution in endosomes and cleavage by β secretase. The α2A AR is a key component of the brain noradrenergic system. Profound noradrenergic dysfunction occurs consistently in patients at the early stages of AD. α2AAR-promoted Aβ generation provides a novel mechanism underlying the connection between noradrenergic dysfunction and AD. Our study also suggests α2AAR as a previously unappreciated therapeutic target for AD. Significantly, pharmacological blockade of the α2AAR by a clinically used antagonist reduces AD-related pathology and ameliorates cognitive deficits in an AD transgenic model, suggesting that repurposing clinical α2AR antagonists would be an effective therapeutic strategy for AD.

Original languageEnglish (US)
Pages (from-to)17296-17301
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number48
DOIs
StatePublished - Dec 2 2014

Fingerprint

Amyloid beta-Protein Precursor
Adrenergic Receptors
Alzheimer Disease
Brain
Pathology
Amyloid Precursor Protein Secretases
Endosomes
Protein Transport
G-Protein-Coupled Receptors
Amyloid
Pharmacology
Peptides
Therapeutics

Keywords

  • Adrenergic receptor |
  • Amyloid |
  • Processing |
  • SorLA |
  • Sorting

ASJC Scopus subject areas

  • General

Cite this

α2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. / Chena, Yunjia; Penga, Yin; Chea, Pulin; Gannona, Mary; Liua, Yin; Lib, Ling; Bu, Guojun D; Van Groena, Thomas; Jiaod, Kai; Wanga, Qin.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 48, 02.12.2014, p. 17296-17301.

Research output: Contribution to journalArticle

Chena, Yunjia ; Penga, Yin ; Chea, Pulin ; Gannona, Mary ; Liua, Yin ; Lib, Ling ; Bu, Guojun D ; Van Groena, Thomas ; Jiaod, Kai ; Wanga, Qin. / α2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 48. pp. 17296-17301.
@article{5eac539b54df4b10a84a15cc24b429fe,
title = "α2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction",
abstract = "Accumulation of amyloid β (Aβ) peptides in the brain is the key pathogenic factor driving Alzheimer's disease (AD). Endocytic sorting of amyloid precursor protein (APP) mediated by the vacuolar protein sorting (Vps10) family of receptors plays a decisive role in controlling the outcome of APP proteolytic processing and Aβ generation. Here we report for the first time to our knowledge that this process is regulated by a G protein-coupled receptor, the α2A adrenergic receptor (α2AAR). Genetic deficiency of the α2AAR significantly reduces, whereas stimulation of this receptor enhances, Aβ generation and AD-related pathology. Activation of α2AAR signaling disrupts APP interaction with a Vps10 family receptor, sort-ing- related receptor with A repeat (SorLA), in cells and in the mouse brain. As a consequence, activation of α2AAR reduces Golgi localization of APP and concurrently promotes APP distribution in endosomes and cleavage by β secretase. The α2A AR is a key component of the brain noradrenergic system. Profound noradrenergic dysfunction occurs consistently in patients at the early stages of AD. α2AAR-promoted Aβ generation provides a novel mechanism underlying the connection between noradrenergic dysfunction and AD. Our study also suggests α2AAR as a previously unappreciated therapeutic target for AD. Significantly, pharmacological blockade of the α2AAR by a clinically used antagonist reduces AD-related pathology and ameliorates cognitive deficits in an AD transgenic model, suggesting that repurposing clinical α2AR antagonists would be an effective therapeutic strategy for AD.",
keywords = "Adrenergic receptor |, Amyloid |, Processing |, SorLA |, Sorting",
author = "Yunjia Chena and Yin Penga and Pulin Chea and Mary Gannona and Yin Liua and Ling Lib and Bu, {Guojun D} and {Van Groena}, Thomas and Kai Jiaod and Qin Wanga",
year = "2014",
month = "12",
day = "2",
doi = "10.1073/pnas.1409513111/-/DCSupplemental",
language = "English (US)",
volume = "111",
pages = "17296--17301",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "48",

}

TY - JOUR

T1 - α2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction

AU - Chena, Yunjia

AU - Penga, Yin

AU - Chea, Pulin

AU - Gannona, Mary

AU - Liua, Yin

AU - Lib, Ling

AU - Bu, Guojun D

AU - Van Groena, Thomas

AU - Jiaod, Kai

AU - Wanga, Qin

PY - 2014/12/2

Y1 - 2014/12/2

N2 - Accumulation of amyloid β (Aβ) peptides in the brain is the key pathogenic factor driving Alzheimer's disease (AD). Endocytic sorting of amyloid precursor protein (APP) mediated by the vacuolar protein sorting (Vps10) family of receptors plays a decisive role in controlling the outcome of APP proteolytic processing and Aβ generation. Here we report for the first time to our knowledge that this process is regulated by a G protein-coupled receptor, the α2A adrenergic receptor (α2AAR). Genetic deficiency of the α2AAR significantly reduces, whereas stimulation of this receptor enhances, Aβ generation and AD-related pathology. Activation of α2AAR signaling disrupts APP interaction with a Vps10 family receptor, sort-ing- related receptor with A repeat (SorLA), in cells and in the mouse brain. As a consequence, activation of α2AAR reduces Golgi localization of APP and concurrently promotes APP distribution in endosomes and cleavage by β secretase. The α2A AR is a key component of the brain noradrenergic system. Profound noradrenergic dysfunction occurs consistently in patients at the early stages of AD. α2AAR-promoted Aβ generation provides a novel mechanism underlying the connection between noradrenergic dysfunction and AD. Our study also suggests α2AAR as a previously unappreciated therapeutic target for AD. Significantly, pharmacological blockade of the α2AAR by a clinically used antagonist reduces AD-related pathology and ameliorates cognitive deficits in an AD transgenic model, suggesting that repurposing clinical α2AR antagonists would be an effective therapeutic strategy for AD.

AB - Accumulation of amyloid β (Aβ) peptides in the brain is the key pathogenic factor driving Alzheimer's disease (AD). Endocytic sorting of amyloid precursor protein (APP) mediated by the vacuolar protein sorting (Vps10) family of receptors plays a decisive role in controlling the outcome of APP proteolytic processing and Aβ generation. Here we report for the first time to our knowledge that this process is regulated by a G protein-coupled receptor, the α2A adrenergic receptor (α2AAR). Genetic deficiency of the α2AAR significantly reduces, whereas stimulation of this receptor enhances, Aβ generation and AD-related pathology. Activation of α2AAR signaling disrupts APP interaction with a Vps10 family receptor, sort-ing- related receptor with A repeat (SorLA), in cells and in the mouse brain. As a consequence, activation of α2AAR reduces Golgi localization of APP and concurrently promotes APP distribution in endosomes and cleavage by β secretase. The α2A AR is a key component of the brain noradrenergic system. Profound noradrenergic dysfunction occurs consistently in patients at the early stages of AD. α2AAR-promoted Aβ generation provides a novel mechanism underlying the connection between noradrenergic dysfunction and AD. Our study also suggests α2AAR as a previously unappreciated therapeutic target for AD. Significantly, pharmacological blockade of the α2AAR by a clinically used antagonist reduces AD-related pathology and ameliorates cognitive deficits in an AD transgenic model, suggesting that repurposing clinical α2AR antagonists would be an effective therapeutic strategy for AD.

KW - Adrenergic receptor |

KW - Amyloid |

KW - Processing |

KW - SorLA |

KW - Sorting

UR - http://www.scopus.com/inward/record.url?scp=84914162459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914162459&partnerID=8YFLogxK

U2 - 10.1073/pnas.1409513111/-/DCSupplemental

DO - 10.1073/pnas.1409513111/-/DCSupplemental

M3 - Article

C2 - 25404298

AN - SCOPUS:84914162459

VL - 111

SP - 17296

EP - 17301

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 48

ER -